Skip to content

A non-inferior, randomized, single-blind, multicentre clinical trial of absorbable additive bone repair materials for filling and repairing incomplete load-bearing bone defects in oral and maxillofacial regions

A non-inferior, randomized, single-blind, multicentre clinical trial of absorbable additive bone repair materials for filling and repairing incomplete load-bearing bone defects in oral and maxillofacial regions

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089517
Enrollment
Unknown
Registered
2024-09-10
Start date
2023-02-21
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incomplete load-bearing bone defects in oral and maxillofacial regions

Interventions

Experimental group:absorbable bone-repairing material by additive manufacturing
Control group: bone filling material of Geistlich Bio-Oss

Sponsors

Huashan Hospital affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 68 Years

Inclusion criteria

Inclusion criteria: 1, 18 years old = age =75 years old, gender is not limited; 2. Maxillofacial bone defect restorers: oral and maxillofacial bone defects are not completely load-bearing; 3. Subjects voluntarily participate in clinical trials and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Participated in other clinical trials within 4 weeks before the start of this trial; 2. For stomatological indications: A. The longest end of the jaw cyst is more than 2cm; b. No teeth on both sides of the extraction site or abnormal teeth. c. The alveolar bone height at the extraction site is not sufficient, or bone increment surgery has been received, such as maxillary sinus lift. d. Subjects whose surgical sites may produce artifacts due to various conditions caused by CT examination, such as metal dentures and porcelain teeth; e, a large number of smokers, smoking more than 5 cigarettes per day in the past three months; 3. Various bone defects caused by invasive and malignant bone tumors; 4. Patients who are undergoing tumor treatment, have a history of radiotherapy or chemotherapy, or are receiving immunosuppressive therapy; 5. Patients who are receiving or have received within the last 3 months drugs that may affect or promote bone metabolism; Systemic diseases that may affect surgical wound healing, such as bone marrow inflammation, osteochondrosis, and bone metabolic diseases; 6. Patients with severe cardiovascular, pulmonary, or other systemic diseases that researchers believe cannot tolerate surgery, such as heart insufficiency (New York Heart Function Scale II or higher); 7, have serious liver and kidney disease or abnormal liver and kidney function (ALT, AST > 2.5 times the normal value, creatinine > 2 times the normal value; Abnormal blood calcium and phosphorus results); 8. Poorly controlled diabetic patients (fasting blood glucose still =8.0mmol/L after drug control); 9. Severely obese patients (BMI=40kg/m2); 10. Known autoimmune disease; 11, long-term adrenal corticosteroid therapy; 12, mental abnormality without behavioral autonomy; 13. Patients with allergic constitution to polymer materials; 14, pregnant, lactating or menstruating women, or people with pregnancy plans within six months; 15. Other conditions that the researcher determines cannot participate in the experiment.

Design outcomes

Primary

MeasureTime frame
Bone fusion rate;

Secondary

MeasureTime frame
Wound healing;Site retention rate;Orbital floor repair rate;Product performance satisfaction;

Countries

China

Contacts

Public ContactXiongzheng Mu

Huashan Hospital affiliated to Fudan University

cranio@vip.163.com+86 138 0170 0660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026